End-stage kidney disease on maintenance hemodialysis
Conditions
Interventions
Intravenous iv iron 200 mg post Hemodialysis session every 4 wks,Intravenous iv iron 100 mg post Hemodialysis session every 2 wks
Experimental Drug,Experimental Drug
Iron iv 200 mg q 4 wks,Iron iv 100 mg q 2 wks
Sponsors
King Taksin Memorial Hospital Research Grant
Eligibility
Sex/Gender
All
Age
20 Years to 74 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 20 years who have been receiving hemodialysis more than 3 months. 2. not responded to oral iron therapy for 3 months. 3. History of absolute iron deficiency and have completed an intravenous iron loading dose of 1,000 mg and continued maintenance dose 100 mg every 4 weeks for no more than 4 months. Before enrollment, hemoglobin level more than 9 g/dL. 4. Serum ferritin levels between 200 to 800 ng/mL and TSAT between 20 to 40%. 5. Patient provide written informed consent and voluntarily participate in the study.
Exclusion criteria
Exclusion criteria: 1. History of blood loss or received blood transfusion within 4 months prior to enrollment. 2. Anemia from other causes. 3. Cancer who are currently receiving treatment. 4. Active infection. 5. Pregnant or breastfeeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Iron overload every 3 month Ferritin more than 800 ng/mL , TSAT more than 40% | — |
Secondary
| Measure | Time frame |
|---|---|
| EPO dose , mortality rate , Hb level , cardiovascular mortality, infection-related events , vascular access thrombosis every 3 months patient record form | — |
Countries
Thailand
Contacts
Public ContactOran Chalapipat
Nephrology Outpatient Clinic , Taksin Hospital
Outcome results
None listed